Global Hyper Immune Globulin Market Research Report 2023

Publication ID:

PB510230499

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The global Hyper Immune Globulin market is projected to reach US$ 2839.8 million in 2029, increasing from US$ 1867 million in 2022, with the CAGR of 6.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hyper Immune Globulin 91制片厂.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hyper Immune Globulin market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Others
Segment by Application
Government Institutions
Private Sector
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hyper Immune Globulin report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Hyper Immune Globulin Market Overview
1.1 Product Overview and Scope of Hyper Immune Globulin
1.2 Hyper Immune Globulin Segment by Type
1.2.1 Global Hyper Immune Globulin Market Value Comparison by Type (2023-2029)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Others
1.3 Hyper Immune Globulin Segment by Application
1.3.1 Global Hyper Immune Globulin Market Value by Application: (2023-2029)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Others
1.4 Global Hyper Immune Globulin Market Size Estimates and Forecasts
1.4.1 Global Hyper Immune Globulin Revenue 2018-2029
1.4.2 Global Hyper Immune Globulin Sales 2018-2029
1.4.3 Global Hyper Immune Globulin Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Hyper Immune Globulin Market Competition by Manufacturers
2.1 Global Hyper Immune Globulin Sales Market Share by Manufacturers (2018-2023)
2.2 Global Hyper Immune Globulin Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Hyper Immune Globulin Average Price by Manufacturers (2018-2023)
2.4 Global Hyper Immune Globulin Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Hyper Immune Globulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hyper Immune Globulin, Product Type & Application
2.7 Hyper Immune Globulin Market Competitive Situation and Trends
2.7.1 Hyper Immune Globulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hyper Immune Globulin Players Market Share by Revenue
2.7.3 Global Hyper Immune Globulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hyper Immune Globulin Retrospective Market Scenario by Region
3.1 Global Hyper Immune Globulin Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Hyper Immune Globulin Global Hyper Immune Globulin Sales by Region: 2018-2029
3.2.1 Global Hyper Immune Globulin Sales by Region: 2018-2023
3.2.2 Global Hyper Immune Globulin Sales by Region: 2024-2029
3.3 Global Hyper Immune Globulin Global Hyper Immune Globulin Revenue by Region: 2018-2029
3.3.1 Global Hyper Immune Globulin Revenue by Region: 2018-2023
3.3.2 Global Hyper Immune Globulin Revenue by Region: 2024-2029
3.4 North America Hyper Immune Globulin Market Facts & Figures by Country
3.4.1 North America Hyper Immune Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Hyper Immune Globulin Sales by Country (2018-2029)
3.4.3 North America Hyper Immune Globulin Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hyper Immune Globulin Market Facts & Figures by Country
3.5.1 Europe Hyper Immune Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Hyper Immune Globulin Sales by Country (2018-2029)
3.5.3 Europe Hyper Immune Globulin Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hyper Immune Globulin Market Facts & Figures by Country
3.6.1 Asia Pacific Hyper Immune Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Hyper Immune Globulin Sales by Country (2018-2029)
3.6.3 Asia Pacific Hyper Immune Globulin Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Hyper Immune Globulin Market Facts & Figures by Country
3.7.1 Latin America Hyper Immune Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Hyper Immune Globulin Sales by Country (2018-2029)
3.7.3 Latin America Hyper Immune Globulin Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hyper Immune Globulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Hyper Immune Globulin Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Hyper Immune Globulin Sales by Country (2018-2029)
3.8.3 Middle East and Africa Hyper Immune Globulin Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hyper Immune Globulin Sales by Type (2018-2029)
4.1.1 Global Hyper Immune Globulin Sales by Type (2018-2023)
4.1.2 Global Hyper Immune Globulin Sales by Type (2024-2029)
4.1.3 Global Hyper Immune Globulin Sales Market Share by Type (2018-2029)
4.2 Global Hyper Immune Globulin Revenue by Type (2018-2029)
4.2.1 Global Hyper Immune Globulin Revenue by Type (2018-2023)
4.2.2 Global Hyper Immune Globulin Revenue by Type (2024-2029)
4.2.3 Global Hyper Immune Globulin Revenue Market Share by Type (2018-2029)
4.3 Global Hyper Immune Globulin Price by Type (2018-2029)
5 Segment by Application
5.1 Global Hyper Immune Globulin Sales by Application (2018-2029)
5.1.1 Global Hyper Immune Globulin Sales by Application (2018-2023)
5.1.2 Global Hyper Immune Globulin Sales by Application (2024-2029)
5.1.3 Global Hyper Immune Globulin Sales Market Share by Application (2018-2029)
5.2 Global Hyper Immune Globulin Revenue by Application (2018-2029)
5.2.1 Global Hyper Immune Globulin Revenue by Application (2018-2023)
5.2.2 Global Hyper Immune Globulin Revenue by Application (2024-2029)
5.2.3 Global Hyper Immune Globulin Revenue Market Share by Application (2018-2029)
5.3 Global Hyper Immune Globulin Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CSL Behring Hyper Immune Globulin Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Grifols Hyper Immune Globulin Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biotest Hyper Immune Globulin Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kedrion Hyper Immune Globulin Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CBPO Hyper Immune Globulin Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Emergent (Cangene) Hyper Immune Globulin Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kamada Hyper Immune Globulin Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CNBG Hyper Immune Globulin Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Hualan Bio Hyper Immune Globulin Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shanghai RAAS Hyper Immune Globulin Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Hyper Immune Globulin Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Sichuan Yuanda Shuyang Hyper Immune Globulin Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Hyper Immune Globulin Description and Business Overview
6.12.3 ADMA Biologics Hyper Immune Globulin Sales, Revenue and Gross Margin (2018-2023)
6.12.4 ADMA Biologics Hyper Immune Globulin Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hyper Immune Globulin Industry Chain Analysis
7.2 Hyper Immune Globulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hyper Immune Globulin Production Mode & Process
7.4 Hyper Immune Globulin Sales and Marketing
7.4.1 Hyper Immune Globulin Sales Channels
7.4.2 Hyper Immune Globulin Distributors
7.5 Hyper Immune Globulin Customers
8 Hyper Immune Globulin Market Dynamics
8.1 Hyper Immune Globulin Industry Trends
8.2 Hyper Immune Globulin Market Drivers
8.3 Hyper Immune Globulin Market Challenges
8.4 Hyper Immune Globulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.